Denovo Biopharma Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
43
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$12M
- Investors
-
27
Denovo Biopharma General Information
Description
Developer of personalized drugs intended to discover biomarker in therapeutic areas including oncology, metabolic, cardiology, immunology and neurology. The company performs de novo genomic biomarker discovery retrospectively using archived clinical samples, enabling biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and less adverse effects.
Contact Information
Website
www.denovobiopharma.comCorporate Office
- Room A1409-1410, Building 2, No. 452
- No. 6 Street, Baiyang Street, Qiantang New District
- Hangzhou, Zhejiang 310018
- China
Corporate Office
- Room A1409-1410, Building 2, No. 452
- No. 6 Street, Baiyang Street, Qiantang New District
- Hangzhou, Zhejiang 310018
- China
Denovo Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 06-May-2024 | $12M | Completed | Clinical Trials - Phase 3 | ||
| 8. IPO | 26-Nov-2021 | Cancelled | Clinical Trials - Phase 3 | |||
| 7. Later Stage VC (Series D) | 07-Dec-2020 | Completed | Clinical Trials - Phase 3 | |||
| 6. Secondary Transaction - Private | 31-Jul-2020 | Completed | Clinical Trials - Phase 3 | |||
| 5. Secondary Transaction - Private | 09-Jul-2020 | Completed | Clinical Trials - Phase 3 | |||
| 4. Later Stage VC (Series C) | 24-Jun-2020 | Completed | Clinical Trials - General | |||
| 3. Later Stage VC (Series B) | 31-Oct-2019 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A) | 16-Jul-2015 | Completed | Clinical Trials - General | |||
| 1. Joint Venture | 21-Feb-2012 | $9.5M | Completed | Generating Revenue |
Denovo Biopharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | ||||||||
| Ordinary Shares | ||||||||
| Ordinary Shares | 18,762,418 | $2.4 | $2.4 | 1x | $2.4 | 4.83% |
Denovo Biopharma Comparisons
Industry
Financing
Details
Denovo Biopharma Competitors (2)
One of Denovo Biopharma’s 2 competitors is BioIVT, a Private Equity-Backed company based in Westbury, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioIVT | Private Equity-Backed | Westbury, NY | ||||
| Almac Group | Venture Capital-Backed | Craigavon, United Kingdom |
Denovo Biopharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Denovo Biopharma Patents
Denovo Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10202652-B2 | Methods and compositions of predicting activity of retinoid x receptor modulator | Active | 08-Jun-2011 | ||
| US-20150368720-A1 | Methods and compositions of predicting activity of retinoid x receptor modulator | Active | 08-Jun-2011 | ||
| US-20140031242-A1 | Method for discovering pharmacogenomic biomarkers | Inactive | 31-Jan-2011 | ||
| US-20210108266-A1 | Method for discovering pharmacogenomic biomarkers | Inactive | 31-Jan-2011 | C12Q1/6874 |
Denovo Biopharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Denovo Biopharma Investors (27)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| California Institute for Regenerative Medicine | Government | Minority | ||
| Beijing Fangsheng Investment Management Center | Growth/Expansion | Minority | ||
| China Resources Capital Management | Corporate Venture Capital | Minority | ||
| Hangzhou Industrial Investment Group | Government | Minority | ||
| Heda Ventures | Venture Capital | Minority |
Denovo Biopharma Investments (4)
Denovo Biopharma’s most recent deal was a Early Stage VC with Hunan Youzhu. The deal was made on 22-May-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Hunan Youzhu | 22-May-2024 | Early Stage VC | Beverages | ||
| Tocagen (Replicating Gene Therapy Platform and Related Assets) | 28-Apr-2020 | Corporate Asset Purchase | Buildings and Property | ||
| Eli Lilly (Enzastaurin) | 16-Sep-2014 | Corporate Asset Purchase | Buildings and Property | ||
| Denovo Biopharma | 21-Feb-2012 | Joint Venture | Drug Discovery |
Denovo Biopharma FAQs
-
When was Denovo Biopharma founded?
Denovo Biopharma was founded in 2012.
-
Where is Denovo Biopharma headquartered?
Denovo Biopharma is headquartered in Hangzhou, China.
-
What is the size of Denovo Biopharma?
Denovo Biopharma has 43 total employees.
-
What industry is Denovo Biopharma in?
Denovo Biopharma’s primary industry is Drug Discovery.
-
Is Denovo Biopharma a private or public company?
Denovo Biopharma is a Private company.
-
What is Denovo Biopharma’s current revenue?
The current revenue for Denovo Biopharma is .
-
How much funding has Denovo Biopharma raised over time?
Denovo Biopharma has raised $151M.
-
Who are Denovo Biopharma’s investors?
California Institute for Regenerative Medicine, Beijing Fangsheng Investment Management Center, China Resources Capital Management, Hangzhou Industrial Investment Group, and Heda Ventures are 5 of 27 investors who have invested in Denovo Biopharma.
-
Who are Denovo Biopharma’s competitors?
BioIVT and Almac Group are competitors of Denovo Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
